Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

But for diabetes and obesity drugs like Ozempic and Zepbound, known as GLP-1s, cheaper copycats emerged almost ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

but an observational study has found that Lilly’s tirzepatide seems to be better at achieving weight loss. Tirzepatide – a dual GLP-1/GIP agonist sold as Mounjaro for diabetes – was ...

Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide has been approved by the FDA as a weight-loss drug.

The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.